Core Session 4: Relapse within 1-3 lines of therapy

Chair(s)

• 

  Philippe Moreau, MD (he/him/his)

  Head of Hematology
  University Hospital Hôtel-Dieu, Nantes, France
  Nantes, Pays de la Loire, France

Co-Chair(s)

• 

  Charlotte Pawlyn, PhD, FRCP, FRCPath (she/her/hers)

  Research Team Leader and Consultant Haematologist
  The Institute of Cancer Research and The Royal Marsden Hospital, United Kingdom

Presentations:

• 09:00 - 09:10 East Coast USA Time

  When to treat relapse: MRD positivity or symptomatic relapse?
  

  Speaker: Fredrik Schjesvold, MD, PhD – Oslo Myeloma Center, Department of Hematology, Oslo University Hospital and KG Jebsen Center for B Cell Malignancies, University of Oslo
• 09:10 - 09:20 East Coast USA Time

  Immunotherapy vs conventional treatment at the time of the first relapse
  

  Speaker: Amrita Krishnan, MD – City of Hope Orange County
• 09:20 - 09:30 East Coast USA Time

  Functional high risk patients at relapse
  

  Speaker: Katja C. Weisel, MD (she/her/hers) – University Medical Center of Hamburg-Eppendorf, Hamburg, Germany
• 09:30 - 09:40 East Coast USA Time

  Should lines of therapy define treatment?
  

  Speaker: Cyrille Touzeau, MD, PhD – CHU Nantes
• 09:40 - 09:55 East Coast USA Time

  Future Directions and Challenges
  

  Speaker: Saad Z. Usmani, MD, MBA, FACP, FASCO – Memorial Sloan Kettering Cancer Center
• 09:55 - 10:20 East Coast USA Time

  Round Table discussion
  

  Panelist: Keith Stewart, MB ChB – Princess Margaret Cancer Centre, University Health Network

  Panelist: Pieter Sonneveld, MD, PhD (he/him/his) – EMN

  Panelist: Meletios A. Dimopoulos – National and Kapodistrian University of Athens, Athens, Greece

  Panelist: Hang Quach, MBBS(Hons) FRACP FRCPA MD (she/her/hers) – St Vincent’s Hospital Melbourne, University of Melbourne, VIC, Australia